Gupta Aditi, Sun Jennifer K, Silva Paolo S
a Beetham Eye Institute, Joslin Diabetes Center , Boston , MA , USA.
b Department of Ophthalmology , Harvard Medical School , Boston , MA , USA.
Semin Ophthalmol. 2018;33(1):42-50. doi: 10.1080/08820538.2017.1353811.
Intravitreous injections are presently the second most frequently performed ophthalmic procedure and the most common vitreoretinal procedure. In diabetic patients, intravitreous injections are frequently performed for the treatment of center-involved diabetic macular edema, proliferative diabetic retinopathy, or other co-existing retinal vascular disease. Diabetic patients may be at higher risk of adverse events compared to non-diabetic individuals, given frequent systemic comorbidities, such as cardiovascular and renal disease and increased susceptibility to infection. This review highlights the potential complications and safety considerations in intravitreous injections in patients with diabetes.
玻璃体内注射目前是第二常见的眼科手术，也是最常见的玻璃体视网膜手术。在糖尿病患者中，玻璃体内注射常用于治疗累及黄斑中心的糖尿病性黄斑水肿、增殖性糖尿病视网膜病变或其他并存的视网膜血管疾病。鉴于糖尿病患者常伴有心血管疾病和肾脏疾病等全身性合并症，且感染易感性增加，与非糖尿病个体相比，他们发生不良事件的风险可能更高。本综述重点介绍了糖尿病患者玻璃体内注射的潜在并发症和安全注意事项。
